This book is a major update of novel targets in angiogenesis modulation, including pro- and anti-angiogenesis. There is in-depth coverage of preclinical and clinical methods and models, investigational status, and clinical applications. The impact of nanotechnology in advancing the applications of pro-and anti-angiogenesis strategies is also highlighted, along with stem cell and biotechnologies in research and development of angiogenesis modulating targets.
This book is a major update of novel targets in angiogenesis modulation, including pro- and anti-angiogenesis. There is in-depth coverage of preclinical and clinical methods and models, investigational status, and clinical applications. The impact of nanotechnology in advancing the applications of pro-and anti-angiogenesis strategies is also highlighted, along with stem cell and biotechnologies in research and development of angiogenesis modulating targets.
Artikelnr. des Verlages: 86234892, 978-94-007-6466-8
2013
Seitenzahl: 216
Erscheinungstermin: 25. Mai 2013
Englisch
Abmessung: 241mm x 160mm x 17mm
Gewicht: 477g
ISBN-13: 9789400764668
ISBN-10: 9400764669
Artikelnr.: 37154768
Herstellerkennzeichnung
Books on Demand GmbH
In de Tarpen 42
22848 Norderstedt
info@bod.de
040 53433511
Inhaltsangabe
Preface.- Angiogenesis assays: an appraisal of current techniques.- Survey of pro-angiogenesis strategies.- Angiogenesis modulation by arachidonic acid - derived lipids: positive and negative regulators of angiogenesis.- Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects.- Actions of steroids and peptide hormones on angiogenesis.- Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation.- Catecholamine neurotransmitters: an angiogenic switch in the tumor microenvironment.- Impact of nanotechnology on therapeutic angiogenesis.- Survey of anti-angiogenesis strategies.- Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-Angiogenesis.- Integrin antagonists and angiogenesis.- Anti-angiogenesis therapy as an adjunct to chemotherapy in oncology.- Anti-vegf strategies in ocular angiogenesis- mediated disorders, with special emphasis on age-related macular degeneration.- Application of nanotechnology to targeting tumor angiogenesis for therapeutic benefit.- Biomarkers of response and resistance to anti-angiogenic treatment.- Speculations on new directions in which angiogenesis may proceed. Index.
Preface.- Angiogenesis assays: an appraisal of current techniques.- Survey of pro-angiogenesis strategies.- Angiogenesis modulation by arachidonic acid - derived lipids: positive and negative regulators of angiogenesis.- Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects.- Actions of steroids and peptide hormones on angiogenesis.- Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation.- Catecholamine neurotransmitters: an angiogenic switch in the tumor microenvironment.- Impact of nanotechnology on therapeutic angiogenesis.- Survey of anti-angiogenesis strategies.- Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-Angiogenesis.- Integrin antagonists and angiogenesis.- Anti-angiogenesis therapy as an adjunct to chemotherapy in oncology.- Anti-vegf strategies in ocular angiogenesis- mediated disorders, with special emphasis on age-related macular degeneration.- Application of nanotechnology to targeting tumor angiogenesis for therapeutic benefit.- Biomarkers of response and resistance to anti-angiogenic treatment.- Speculations on new directions in which angiogenesis may proceed. Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826